Octreotide: A Long-Acting Somatostatin Analog

Brown, Nancy J.

doi:10.1097/00000441-199010000-00011

Cited by 11 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single dose of 200 tg sandostatin is the maximum dose currently recommended for intravenous application in the majority of clinical trials. Furthermore, almost all effects of the drug were observed after application of a single dose (Brown, 1990;. In this trial baseline concentrations of somatostatin as well as the increase in serum levels following intravenous application were in accordance with published pharmacokinetic data Schmidt, 1986 Kutz et al, 1986).…”

Section: Histology and Srif-receptor Autoradiographysupporting

confidence: 88%

“…less than 3 minutes. Octreotide (SMS 20 1-995, San-dostatin®) is a synthetic octapeptide with a biologic half life between 45 and 115 minutes, is analogous to and more potent than somatostatin (Brown, 1990;. In clinical trials it is used with some success in the treatment of various tumors e.g.…”

Section: Introductionmentioning

confidence: 99%

“…In clinical trials it is used with some success in the treatment of various tumors e.g. pituitary (growth hormone) adenoma, gastrinoma and neuroblastoma (Brown, 1990; . Since parathyroid tissue shares many of the properties of other endo-Introduction Non-operative treatment options for patients with primary hyperparathyroidism (pHPT) are limited.…”

Section: Introductionmentioning

confidence: 99%

“…Since parathyroid tissue shares many of the properties of other endo-Introduction Non-operative treatment options for patients with primary hyperparathyroidism (pHPT) are limited. Somatostatin (SRIF) has been used for symptomatic treatment of various endocrine tumors (Brown, 1990;Shiomo, 1990). The effectiveness is based on the expression of specific high affinity SRIFreceptors in these tissues.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

Hasse

Zielke²,

Bruns³

et al. 2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Somatostatin (SRIF) is effective in the nonoperative management of a variety endocrine tumors. A potential role of SRIF for treatment of patients with primary hyperparathyroidism (pHPT) has been suggested. In a controlled, prospective, triple-blinded, randomized clinical trial, the somatostatin analogue octreotide (SMS 201-995, Sandostatin) was evaluated in 40 patients with well documented pHPT. Amongst other biochemical parameters, serum calcium and-phosphate and levels of parathyroid hormone, calcitonin, and osteocalcin as well as octreotide were assessed before and for 4 hours after a single iv. application of 200 micrograms ocreotide or placebo. SRIF-receptor autoradiography was performed in parathyroid tissue samples. Baseline values revealed a constellation of biochemical parameters typically found in pHPT. Following 200 micrograms octreotide, no significant changes in any of the biochemical parameters investigated for were observed. Multivariate analysis was performed to identify patient subpopulations in which any given combination of laboratory parameters changed in response to either drug or placebo. However, no 'responders' to octreotide were identified. 45% of patients receiving octreotide, reported side effects. Parathyroid tissue samples were negative for SRIF-receptor expression. It is concluded that a single dose iv. application of octreotide does not result in appreciable changes of biochemical parameters relevant in pHPT and carries a high rate of side effects. Furthermore, absence of SRIF-receptors in parathyroid tissue from patients with pHPT, together with lack of octreotide effects, suggests that somatostatin-analogues may not be effective in the non-operative therapy of pHPT.

show abstract

Section: Histology and Srif-receptor Autoradiographysupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

Hasse

Zielke²,

Bruns³

et al. 2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Somatostatin-secret ing cells are present in the central nervous (hy pothalamus, periventricular nuclei, eminentia medialis and extrahypothalamic regions) and gastrointestinal (stomach, small intestine and pancreatic D cells) systems. In addition, the vagal nerves, the submucosal and myen teric plcxi of the gastrointestinal system, the kidney, the thyroidal gland, the eye and the salivary glands contain somatostatin [26][27][28]. When the results of the somatostatin group were evaluated, the regeneration criteria on the 1st and 3rd days postoperatively were found to be significantly lower when com pared with the control group.…”

Section: Discussionmentioning

confidence: 99%

Effects of Cyclosporin and Somatostatin on Liver Regeneration after Partial Hepatectomy in Rats

Kapan

İpek²,

Sa'D³

et al. 1996

Eur Surg Res

View full text Add to dashboard Cite

The major hepatic reaction which occurs in response to degeneration or partial loss of the liver is compensatory hyperplasia. After finding out that hemodynamic factors have no influence in hepatic regeneration, the investigations have been focused on some trophic factors which have been found in the blood and which have been believed to provide the basic control of regeneration. In our controlled experimental study we have tried to evaluate the effects on hepatic regeneration of cyclosporin and somatostatin which are known to act on the hepatic regeneration ability or which are thought to have effects on regeneration because of their mechanism of action. For the purpose of evaluating the regenerative response findings like the weight of the regenerated liver, mean Ag nuclear organizer region (AgNOR) number, the mitosis index, cells with double nuclei and hyperchromatic nucleus were taken into consideration. The results of the cyclosporin group were higher than of the controls, but there was no statistically significant difference between them. In the somatostatin group, an inhibition of regeneration related to the dose and to the duration at the beginning and a delayed augmentation of the regeneration rate due to the withdrawal of the drug were observed. Values of AgNOR were significantly higher compared to the control group on the 5th day postoperatively, while the liver weight was lower on the 1st day (p < 0.05).

show abstract

Endothelins 1 and 3: Potent cholestatic agents secreted and excreted by the liver that interact with cyclosporine

et al. 1993

View full text Add to dashboard Cite

Autoradiographic studies have shown that the liver accumulates endothelin. High-affinity binding sites for endothelin have been identified on rat liver plasma membranes. We investigated the role of endothelin isopeptides as mediators of cholestasis with isolated rat liver perfused by a recirculating solution of buffer and blood. These studies demonstrated that endothelin-1, as measured by means of radioimmunoassay, was cleared from the perfusate by the liver and that the liver concentrated both endothelin-1 and endothelin-3 in bile. Addition of endothelin-1 to the liver perfusate solution increased the concentration of endothelin-3 measured in the perfusate, suggesting that endothelin-1 caused release or secretion of endothelin-3. Both endothelin-1 and endothelin-3 at 5 nmol/L caused almost complete cessation of bile flow, but this effect was more prolonged after endothelin-1 than after endothelin-3 administration. Because it has been reported that cyclosporine increases endothelin levels, we studied the interaction of these two compounds. Cyclosporine (100 mumol/L) also produced cholestasis. Endothelin-3 secretion in bile, however, was decreased in livers perfused with cyclosporine compared with secretion in controls. Simultaneous addition of endothelin-1 and cyclosporine that on their own were not significantly cholestatic produced cholestasis. In conclusion, endothelin is a potent cholestatic agent secreted and excreted by the liver. It may potentiate the cholestatic action of cyclosporine.

show abstract

Octreotide: A Long-Acting Somatostatin Analog

Cited by 11 publications

References 59 publications

Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

Effects of Cyclosporin and Somatostatin on Liver Regeneration after Partial Hepatectomy in Rats

Endothelins 1 and 3: Potent cholestatic agents secreted and excreted by the liver that interact with cyclosporine

Contact Info

Product

Resources

About